Stothers, Christopher;
Galea, Alessandra;
(2022)
The best medicine? Competition law and generics pricing in the UK.
Competition Law Insight
, 21
(8)
Preview |
Text
The-best-medicine.pdf - Published Version Download (232kB) | Preview |
Abstract
Innovative medicines are typically guaranteed the protection of patents and various forms of market exclusivity, in order to allow innovators sufficient return on their investment to incentivise the costly research and development required. Once those patents and exclusivity expire, other companies can launch generic copies of the medicines, which tends to drive the price down through the process of competition. However, how does the system cope if competition in those generic drugs dries up? This article explores the competition law implications which may arise in such cases.1
| Type: | Article |
|---|---|
| Title: | The best medicine? Competition law and generics pricing in the UK |
| Open access status: | An open access version is available from UCL Discovery |
| Publisher version: | https://www.competitionlawinsight.com/industry-sec... |
| Language: | English |
| Additional information: | This version is the version of record. For information on re-use, please refer to the publisher’s terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > UCL SLASH UCL > Provost and Vice Provost Offices > UCL SLASH > Faculty of Laws |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10193275 |
Archive Staff Only
 |
View Item |
